BiomX Inc. (NYSEAMERICAN:PHGE) Short Interest Down 50.6% in February

BiomX Inc. (NYSEAMERICAN:PHGE) was the target of a significant decline in short interest in February. As of February 13th, there was short interest totaling 133,660 shares, a decline of 50.6% from the January 29th total of 270,744 shares. Approximately 10.7% of the shares of the stock are sold short. Based on an average daily trading volume, of 147,073 shares, the days-to-cover ratio is presently 0.9 days. Based on an average daily trading volume, of 147,073 shares, the days-to-cover ratio is presently 0.9 days. Approximately 10.7% of the shares of the stock are sold short.

Institutional Investors Weigh In On BiomX

An institutional investor recently bought a new position in BiomX stock. Citadel Advisors LLC acquired a new stake in shares of BiomX Inc. (NYSEAMERICAN:PHGE) in the 3rd quarter, according to the company in its most recent disclosure with the SEC. The institutional investor acquired 161,781 shares of the company’s stock, valued at approximately $85,000. Citadel Advisors LLC owned approximately 0.61% of BiomX at the end of the most recent quarter. 40.57% of the stock is currently owned by hedge funds and other institutional investors.

BiomX Price Performance

Shares of BiomX stock opened at $4.57 on Friday. The stock has a market capitalization of $7.27 million, a P/E ratio of -0.18 and a beta of 1.66. The business has a 50 day simple moving average of $3.86 and a two-hundred day simple moving average of $6.81. BiomX has a 12 month low of $1.50 and a 12 month high of $14.71.

Analyst Upgrades and Downgrades

Separately, HC Wainwright reiterated a “buy” rating on shares of BiomX in a research report on Tuesday, November 25th. One equities research analyst has rated the stock with a Buy rating, According to data from MarketBeat, the company currently has a consensus rating of “Buy” and an average price target of $26.00.

BiomX Company Profile

BiomX Inc is a clinical-stage biotechnology company that specializes in developing precision bacteriophage therapies to target pathogenic bacteria in the human microbiome. By harnessing the natural ability of bacteriophages to selectively infect and lyse harmful bacterial strains, BiomX aims to restore microbial balance without disrupting beneficial commensal organisms. The company’s platform integrates phage discovery, formulation and genetic engineering to create tailored phage cocktails for a range of microbiome-associated diseases.

The company’s pipeline includes lead clinical candidates for gastrointestinal disorders such as pouchitis and ulcerative colitis, as well as programs addressing dermatological indications including acne and atopic dermatitis.